Tenon Medical Q1 Net Loss Narrows to $3.48M; Going Concern Doubt
Tenon Medical, Inc. reported a significant increase in revenue and gross profit for the first quarter of 2026, with revenue rising 89.9% to $1.38 million and gross profit surging 192.6% to $0.95 million. The company also narrowed its net loss to $3.48 million from $3.62 million in the prior year period. However, the company disclosed substantial doubt about its ability to continue as a going concern and received a Nasdaq notice for failing to meet the minimum bid price requirement. Additionally, Tenon Medical issued $4.3 million in gross proceeds from convertible promissory notes to address liquidity needs.
Key Highlights
- Tenon Medical Q1 revenue increased 89.9% to $1.38 million from $0.73 million year-over-year.
- Gross profit surged 192.6% to $0.95 million from $0.32 million year-over-year.
- Net loss narrowed to $3.48 million for Q1 2026, compared to $3.62 million in Q1 2025.
- Net loss per share improved to $(0.31) from $(1.01) year-over-year.
- Issued $4.3 million in gross proceeds from convertible promissory notes in March 2026.
- Net cash used in operating activities increased to $2.96 million from $2.48 million year-over-year.
- Received Nasdaq notice for not meeting the $1.00 minimum bid price rule, with a compliance period until August 24, 2026.
- Expressed substantial doubt about the Company's ability to continue as a going concern for the next year.
Price Impact
More from TNON
Tenon Medical Increases Executive Salaries, Bonuses; Extends Ferrari's Term
Tenon Medical Amends Bylaws, Changes Stockholder Meeting Quorum
Tenon Medical Receives Nasdaq Delisting Notice for Equity Non-Compliance